PsychoGenics supports development of the next generation of drugs to treat CNS disorders by providing a broad range of target screening, discovery and validation resources to pharmaceutical and biotech companies, academic institutions and not-for-profit research foundations. Business agreements range from consulting and designing drug discovery strategies, to fee-for-service testing, to onsite research training and management.

The company has approximately 140 research and support staff, of which more than 35 have Ph.D.s and oversee the offered 50 validated in vivo behavioral tests. PsychoGenics is constantly updating its services by developing new behavioral models and approaches to behavioral testing.

• Breeding
• Genotyping
• Behavioral Pharmacology
• Phenotyping
• Microdialysis
• Radiotelemetry

PsychoGenics has established protocols and Standard Operating Procedures for the array of pharmacologically validated tests it offers. The company is also flexible and can modify protocols and establish new tests to address client needs. Client work will not proceed until all tests pass PsychoGenics' stringent validation requirements.

PsychoGenics has relationships with more than 100 pharmaceutical and biotech companies, and not-for-profit institutions, including Astra Zeneca, Eli Lilly & Company, Sepracor, F. Hoffmann-La Roche, Lundbeck, Harvard Medical School/Massachusetts General Hospital, the ALS Association, SMA Foundation and CHDI. Eighty five percent of the company's current business is repeat business.

The vast majority of PsychoGenics' research staff has extensive pharmaceutical experience; thirty-five of whom have Ph.Ds. All research staff are highly trained in GLP standards and training records are available to our clients. Training is overseen by a GLP-trained Director of Quality Control and Safety. Among PsychoGenics' areas of expertise is mouse behavior, including knowledge of the behavioral and neurological characteristics of the strains most commonly used to produce transgenic mice. Most of the tests in PsychoGenics' recommended battery of behavioral assays have been studied in multiple strains of mice and rats.

All work conducted in PsychoGenics' 65,000 sq. ft. AAALAC accredited facilities is supervised by a senior veterinarian. The highest standards of animal care are implemented to ensure that the facility is pathogen-free and that all animals are healthy. Two recent complete health reports must be provided for all animals entering the facility and a three-week quarantine is required for all non-vendor mice.